Citation 135378
IVANOVSKA,N: PHILIPOV,S:. (1996). STUDY ON THE ANTI-INFLAMMATORY ACTION OF BERBERIS VULGARIS ROOT EXTRACT, ALKALOID FRACTIONS AND PURE ALKALOIDS.. 18(10)
Citation Details
| Title | STUDY ON THE ANTI-INFLAMMATORY ACTION OF BERBERIS VULGARIS ROOT EXTRACT, ALKALOID FRACTIONS AND PURE ALKALOIDS. |
|---|---|
| Authors | IVANOVSKA,N: PHILIPOV,S: |
| Year | 1996 |
| Volume | 18 |
| Issue | 10 |
Summary
Year: 1996
Journal: Unknown
Organisms and Their Experiments (1)
Berberis vulgaris (BERBERIDACEAE)
| Experiment # | Pharmacology Type | Worktypes | Compound | Results |
|---|---|---|---|---|
| 1 |
ANTIINFLAMMATORY ACTIVITY
| None |
WEAK ACTIVITY
|
|
| 2 |
ANTIINFLAMMATORY ACTIVITY
| None |
WEAK ACTIVITY
|
|
| 3 |
ANTIINFLAMMATORY ACTIVITY
| None |
ACTIVE
|
|
| 4 |
ANTIINFLAMMATORY ACTIVITY
| None |
ACTIVE
|
|
| 5 |
ANTIINFLAMMATORY ACTIVITY
| None |
ACTIVE
|
|
| 6 |
ANTIINFLAMMATORY ACTIVITY
| None |
ACTIVE
|
|
| 7 |
INFLAMMATION INDUCTION
| None |
ACTIVE
|
|
| 8 |
COMPLEMENT ALTERNATIVE PATHWAY INHIBITION
| None |
ACTIVE
|
|
| 9 |
COMPLEMENT ALTERNATIVE PATHWAY INHIBITION
| None |
ACTIVE
|
|
| 10 |
COMPLEMENT-CLASSICAL PATHWAY STIMULATION
| None |
ACTIVE
|
|
| 11 |
COMPLEMENT-ALTERNATE PATHWAY STIMULATION
| None |
WEAK ACTIVITY
|
|
| 12 |
COMPLEMENT-ALTERNATE PATHWAY STIMULATION
| None |
ACTIVE
|
|
| 13 |
DELAYED TYPE CUTANEOUS HYPERSENSITIVITY INHIBITION
| None |
ACTIVE
|
|
| 14 |
ANTIBODY FORMATION SUPPRESSION
| None |
ACTIVE
|
|
| 15 |
VASCULAR PERMEABILITY DECREASED
| None |
WEAK ACTIVITY
|
|
| 16 | Not specified | None | ||
| 17 |
COMPLEMENT-ALTERNATE PATHWAY STIMULATION
|
WEAK ACTIVITY
|
||
| 18 |
VASCULAR PERMEABILITY DECREASED
|
ACTIVE
|
||
| 19 |
ANTIINFLAMMATORY ACTIVITY
|
WEAK ACTIVITY
|
||
| 20 |
INFLAMMATION INDUCTION
|
WEAK ACTIVITY
|
||
| 21 |
INFLAMMATION INDUCTION
|
ACTIVE
|
||
| 22 |
COMPLEMENT CLASSICAL PATHWAY INHIBITION
|
ACTIVE
|
||
| 23 | Not specified | None | ||
| 24 |
INFLAMMATION INDUCTION
|
ACTIVE
|
||
| 25 |
DELAYED TYPE CUTANEOUS HYPERSENSITIVITY STIMULATION
|
WEAK ACTIVITY
|
||
| 26 |
ANTIBODY FORMATION SUPPRESSION
|
WEAK ACTIVITY
|